Dharwad News Today

With an influx of 50+ pharmaceutical companies and novel therapies, the Biliary Tract Cancers pipeline is booming

 Breaking News
  • No posts were found

With an influx of 50+ pharmaceutical companies and novel therapies, the Biliary Tract Cancers pipeline is booming

August 12
21:00 2021
With an influx of 50+ pharmaceutical companies and novel therapies, the Biliary Tract Cancers pipeline is booming
Biliary Tract Cancers Pipeline
DelveInsight’s Biliary Tract Cancers (BTCs) pipeline report provides comprehensive insights into 50+ companies and 50+ pipeline drugs in the Biliary Tract Cancers (BTCs) pipeline landscape. It also includes clinical and nonclinical stage products in the pipeline drug profiles and also examines therapeutics by product type, stage, route of administration, and molecule.

DelveInsight’s Biliary Tract Cancers (BTCs) pipeline report provides comprehensive insights into 50+ companies and 50+ pipeline drugs in the Biliary Tract Cancers (BTCs) pipeline landscape. It also includes clinical and nonclinical stage products in the pipeline drug profiles and also examines therapeutics by product type, stage, route of administration, and molecule.

Some of the Key Highlights from the Biliary Tract Cancers Pipeline Report

  • There are currently 50+ drugs in the Biliary Tract Cancers pipeline.

  • The Biliary Tract Cancers pipeline comprises therapies that are in different stages of the clinical phase include Bintrafusp Alfa (M7824), MRG003, RC48-ADC, Nal-Irinotecan and Nivolumab, SO-C101, ZKAB001, and others and are expected to be available for Biliary Tract Cancers treatment soon.

  • Several pharmaceutical companies are evaluating their drug candidates for Biliary Tract Cancers treatment include Merck KGaA, Shanghai Miracogen Inc., RemeGen Co., Ltd., Bristol-Myers Squibb, Sotio a.s., Lee’s Pharmaceutical Limited, among others.

  • Merck Pharmaceuticals released topline data from the Phase II [email protected] BTC 047 study on March 20, 2021, evaluating Bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic Biliary Tract Cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy.

  • Some other pipeline therapies in the late-stage clinical development for Biliary Tract Cancers include MRG003 (Shanghai Miracogen Inc.), RC48-ADC (RemeGen Co., Ltd), along with others.

  • Nal-Irinotecan and Nivolumab are being developed and investigated in Phase I/II studies by Bristol-Myers Squibb for Biliary Tract Cancers treatment.

Request for the sample to get an overview of pipeline landscape @ Biliary Tract Cancers vs Cholangiocarcinoma

Biliary Tract Cancers: Overview

Biliary Tract Cancer (BTC) is a rare and often fatal cancer. It is divided into three types: gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC), and extrahepatic cholangiocarcinoma (eCC), each with its own genetic, risk factor, and clinical presentation. Cancer can develop in any part of the bile duct, but the type of bile duct cancer is determined by the location of the primary tumor (inside or outside the liver) and the type of cell involved.

Biliary Tract Cancers Symptoms 

Bile Duct Cancer usually does not cause symptoms until later in the disease’s progression, but symptoms can appear earlier and lead to an early diagnosis. Jaundice, loss of appetite, greasy stools, dark urine, and abdominal pain are Biliary Tract Cancer symptoms.

Biliary Tract Cancers Treatment

Surgery, radiation therapy, gastroenterology procedures, and, in some cases, novel investigative approaches are among the treatment options for Bile Duct Cancer. The size and location of each patient’s tumors aid in the development of a personalized treatment plan. 

Biliary Tract Cancers Pipeline Analysis: Drug Profiles 

Bintrafusp alfa (M7824): Merck KGaA

Product Description

Bintrafusp alfa (M7824), a potential first-in-class investigational bifunctional fusion protein designed to simultaneously block two immunosuppressive pathways, TGF- and PD-L1, within the tumor microenvironment, was discovered in-house at Merck and is currently in clinical development through a strategic alliance with GSK.

Phase II/III

NCT04066491: Merck Pharmaceuticals, in collaboration with EMD Serono Research & Development Institute, Inc., began a phase II/III multicenter, randomized, placebo-controlled study of gemcitabine plus cisplatin with or without Bintrafusp Alfa (M7824) as first-line treatment for biliary tract cancer in September 2019.

Biliary Tract Cancers Pipeline Therapies and Key Companies

  • Bintrafusp Alfa (M7824): Merck KGaA

  • MRG003: Shanghai Miracogen Inc.

  • RC48-ADC: RemeGen Co., Ltd.

  • Nal-Irinotecan and Nivolumab: Bristol-Myers Squibb

  • SO-C101: Sotio a.s.

  • ZKAB001: Lee’s Pharmaceutical Limited

For more information on the emerging drugs and companies, visit Biliary Tract Cancers Therapies 

Biliary Tract Cancers Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Biliary Tract Cancers Key Players: Merck KGaA, Shanghai Miracogen Inc., RemeGen Co., Ltd., Bristol-Myers Squibb, Sotio a.s., Lee’s Pharmaceutical Limited, among others

Biliary Tract Cancers Pipeline Therapies: Bintrafusp Alfa (M7824), MRG003, RC48-ADC, Nal-Irinotecan and Nivolumab, SO-C101, ZKAB001, and others

Table of Contents 

1.

Introduction

2.

Executive Summary

3.

Biliary Tract Cancers: Overview

4.

Biliary Tract Cancers- Analytical Perspective In-depth Commercial Assessment

5.

Biliary Tract Cancers Pipeline Therapeutics

6.

Biliary Tract Cancers Mid Stage Products

7.

Biliary Tract Cancers Early Stage Products (Phase I)

8.

Biliary Tract Cancers Therapeutic Assessment

9.

Biliary Tract Cancers Inactive Products

10.

Biliary Tract Cancers Company-University Collaborations (Licensing/Partnering) Analysis

11.

Biliary Tract Cancers- Key Companies

12.

Biliary Tract Cancers- Key Products

13.

Biliary Tract Cancers- Unmet Needs

14.

Biliary Tract Cancers- Market Drivers and Barriers

15.

Biliary Tract Cancers- Future Perspectives and Conclusion

16.

Biliary Tract Cancers- Analyst Views

17.

Appendix

18.

About DelveInsight

Key questions answered in the Biliary Tract Cancers Pipeline Report

  • What are the treatment options for cancers of the biliary tract?

  • How many pharmaceutical companies are working on bile duct cancer cures?

  • Which of these companies’ pharmaceuticals is the most commonly used?

  • How many medications for Biliary Tract Cancers does each company produce in total?

  • How many drugs are in the early, middle, or late stages of development in the Biliary Tract Cancers pipeline?

  • How many of the therapies in development can be used alone or in combination with other treatments?

  • What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices impacting Biliary Tract Cancers?

Related Reports

Intrahepatic Cholangiocarcinoma Pipeline Insights 

Get a comprehensive analysis of Intrahepatic Cholangiocarcinoma pipeline therapies and key companies including Basilea Pharmaceutical, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., among others.

Related Posts

Biliary Tract Cancers Emerging Therapeutics and Players 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/dharwadnewstoday.org/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share